Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trialThe late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.[Collection]

The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.https://www.cnbc.com/2024/08/20/eli-lilly-weight-loss-drug-cuts-risk-of-developing-diabetes-in-trial.html